Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q4 2022 Earnings Presentation
19 slides from Bactiguard Holding Ab's earnings presentation, Feb 9, 2023
Slide 1: Investor presentation Q4/Year-end Report 2022
Investor presentation Q4/Year-end Report 2022 February 9, 2023 Anders Göransson, CEO Carin Jakobson, CFO
Slide 2: A strong year for Bactiguard – investments in organization to capture future growth
A strong year for Bactiguard – investments in organization to capture future growth The audiocast will begin shortly 2
Slide 3: 2022 in brief
2022 in brief Rise of infections a serious threat to global health – Bactiguards’ offering provides solutions • Strong year with revenues of 253 MSEK – +42 percent (for Q4 +57 percent) • Well positioned to capture growth opportunities – investments in organization to strengthen capabilities • Strong
Slide 4: Opportunities behind critical global healthcare trends
Opportunities behind critical global healthcare trends Saving lives by preventing infections The issues Therapeutic areas market size • Rise of infections and increased antibiotics use a Orthopedics 40 threat to global health and modern medicine • Multi-resistant bacteria a “silent pandemic” Urology
Slide 5: Key financials Q4 2022 (Q4 2021) and events
Key financials Q4 2022 (Q4 2021) and events Strong revenue growth of 57% (adjusted for currency effects 23% compared to Q4 2021) Revenue EBITDA Net Profit Operating cash flow MSEK 72.2 (46.1) License 46.3 (24.7) MSEK -1.1 (-12.1) MSEK -14.2 (-25.4) MSEK 3.1 (-12.8) BIP 14.9 (17.3) Key events: • Expa
Slide 6: Highlights – License business Q4 and 2022
Highlights – License business Q4 and 2022 License New licenses Revenues Q4 2022 MSEK 7.4 (1.1) Revenues Q4 2022 NA%* MSEK 38.9 (23.6) +65%* Goal met: two new license partnerships in 2022 Becton, Dickinson & Company Zimmer Biomet Trauma Zimmer Biomet • Remains largest license partner • Contract manuf
Slide 7: Highlights – Zimmer Biomet Trauma Q4 and 2022
Highlights – Zimmer Biomet Trauma Q4 and 2022 ZIMMER BIOMET TRAUMA • Zimmer® Natural Nail® (ZNN) Bactiguard- implants launch continues across EMEA • Regulatory efforts for ZNN Bactiguard implants approval in more key markets continues – US approval will be a key milestone • Expanded clinical evidenc
Slide 8: Highlights – BIP product portfolio Q4 and 2022
Highlights – BIP product portfolio Q4 and 2022 PRODUCT PORTFOLIO • Sales lower than anticipated ‒ Restructuring of sales organization ‒ Supply issues related to sutures ‒ Post-covid issues still affecting healthcare system Revenues Q4 2022 ‒ Strategic investments in commercial offering MSEK 14.9 (17
Slide 9: Financials
Financials Keeping people safe from infections 9
Slide 10: Rolling 12-month revenue
Rolling 12-month revenue RTM development, MSEK 250 80,0 • Rolling 12-months revenue numbers at all-time high 200 60,0 • License - BD volume stable on a high 40,0 level 150 - Growing business from Revenues EBITDA 20,0 Zimmer Biomet 100 • BIP product portfolio grew by 0,0 9% driven by India, Nordics a
Slide 11: Financial overview 2022 vs 2021
Financial overview 2022 vs 2021 • Strong year Amounts in TSEK 2022 2021 2022 2021 • Revenues MSEK 253.5 (179) – Oct-Dec Oct-Dec Full year Full year increase of 42% though higher license revenue of 42% and 9% higher BIP revenue Total revenues 72.2 46.1 253.5 179.0 EBITDA -1.1 -12.1 -6.4 -7.2 • EBITDA
Slide 12: Cash flow and liquidity
Cash flow and liquidity Cash flow and liquidity, MSEK • Strong financial position 300 40 • Cash flow from operating activities Q4 7.0 (11.6) MSEK 250 30 • Available liquidity incl. overdraft facility 228 (248) MSEK 200 20 Cash flow Liquidity 150 10 100 0 50 -10 0 -20 Cash and cash equivalent Overdra
Slide 13: Q&A / To summarize
Q&A To summarize Keeping people safe from infections 13 13
Slide 14: Well positioned for sustainable growth
Well positioned for sustainable growth Critical prerequisites in place 1 2 3 Clinical evidence & Capital for growth Investments in organization regulatory • Commercial capabilities strengthened • >200 million catheters used, no reported for continued expansion adverse event • Resources allocated to
Slide 15: Outlook – drivers to deliver on 2026 financial goals
Outlook – drivers to deliver on 2026 financial goals The need for infection prevention has never been greater For illustrative purposes * Today Existing license customers (trauma) 15 * Currently a global development partnership with a license option
Slide 16: Capitalizing on the US market opportunity a key priority
Capitalizing on the US market opportunity a key priority Represents around 31% of the global MedTech market 540 • Huge potential for Bactiguard’s offering of infection (USDbn) prevention solutions and products Global MedTech Market US 31% • Product approvals key and an “entrance barrier” ‒ Approval
Slide 17: Growth strategy kick-started
Growth strategy kick-started Recap of today’s presentation • Strong year • Achieved goal of two new license partnerships • Investments in the organization to strengthen capabilities • Global healthcare macro trends present growth opportunities and potential to make positive impact with our infection
Slide 18: Top Swedish medical innovations list
Har ar hela listan — De viktigaste svenska medicininnovationerna Losec (Astra, Ivan Ostholm, Sven-Erik Sjéstrand, Enar Carlsson m.fl.) . Rullatorn (Aina Wifalk) . Healon/Xalatan (Pharmacia, Endre A. Balazs, Johan Stjernschantz m.fl.) . Turbuhaler (Draco, Kjell Wetterlin, m.fl.) . Curosurf (Karolinsk
Slide 19: Questions & Answers
Questions & Answers Anders Göransson Carin Jakobson CEO CFO +46 8 440 58 80 +46 8 440 58 80 anders.goransson@bactiguard.com carin.jakobson@bactiguard.com 19